



ICR Governing Board Meeting Minutes

September 9, 2022 12:00 – 1:00 pm

Meeting By Zoom: <https://csupueblo.zoom.us/j/94716990351>

In attendance: Dr. Cinnamon Bidwell, Dr. Chad Kinney, Dr. Jeff Smith, Dr. Sue Sisley, Dr. Jon Reuter, Dr. Joanna Zeiger, Mr. John Lord, Mr. Sherard Rogers, and Mr. Scott McWhorter;

Absent: Mr. Sal Pace, Dr. Malik Hasan, Dr. Tim Mottet, and Ms. Elyse Contreras

I. Dr. Bidwell welcomed ICR attending Governing Board members to the meeting.

II. The consent Agenda was presented by Dr. Bidwell.

The consent agenda was approved by unanimous vote; 7 in favor with a motion to approve put forth by Dr. Sisley and seconded by Dr. Zeiger.

III. An update on progress hiring a PR/Marketing consultant was given by Dr. Smith.

Four proposals were received by the deadline on the 8th of September. ICR staff will screen the proposals and Dr. Smith will discuss the results with Dr. Bidwell. Dr.'s Smith and Bidwell will then bring forward the best candidates to the board for a final decision on whom to offer a contract to. No objections were raised.

IV. An update on progress organizing funds for the lobbyists and Medpharm project was provided by Dr. Smith.

Dr. Smith reported good news that the check will be cut on Tuesday the 13th of September and that the process can now move forward. Dr. Bidwell noted she was pleased and sees this as a high priority for the board.

V. Dr.'s Bidwell and Smith led discussion about the quality of the recent Cannabis Research Conference, CRC22, and solicited input from the board on how to respond constructively as the ICR begins planning CRC23.

CRC22:

Dr. Smith presented highlights of the Post Event Report which was provided by Daphne Plump and distributed to the board for review. There was \$37,000 generated and 221 attendees in total. Technical difficulties with short transition times between sessions and problems for presenters in logging into virtual sessions were reported. Dr. Zeiger noted only 28 people participated in the surveys calling the survey-validity into question. It was noted that the ICR has a similar final report from CRC21 and that it would be good to have this for comparison. Wendy Fairchild was asked to distribute the report to the board. It was suggested by Dr.'s Smith, Kinney, Bidwell and Zeiger that the virtual format largely contributed to decreased attendance and improvement is likely with CRC23 being in-person.

CRC23:

Dr. Zeiger noted that she would like to see a broader scope of topics and Dr. Bidwell agreed. Dr. Zeiger would like increased clinical, medical, and epidemiological tracks. Dr. Zeiger questioned the value of the ICR collaboration with OSU Global Hemp Innovation Center. Dr. Kinney was asked to provide input and suggested both stature and attendance will be increased as a result of collaborative partnerships and evidence of that should be evaluated next year.

Dr. Smith reported CRC23 will be the Auraria Campus Convention Center in Denver, Aug 7-9. ICR has a program committee chair in place and will network with various organizations and individuals to build the program. Dr. Zeiger volunteered to be on the programming committee.

Dr. Bidwell would like to highlight the board members, increase inclusion of their ideas, and asked members to consider sponsors, marketing ideas, etc. Dr. Smith encouraged participation from the board. Dr. Kinney noted sponsors were secured by Daphne Plump, Consulting. ICR will review sponsors from previous conferences and work to enhance sponsorship. Scott McWhorter suggested big companies should be involved; e.g. Perkin-Elmer was last year. The board was reminded ICR cannot take funds from federally illegal businesses.

VI. Dr. Bidwell led discussion on first-quarter goals and evaluation for the Interim Director, and solicited feedback from board members. An evaluation template was distributed to the board for review and no objections were raised. As Dr. Smith's direct supervisor, Dr. Kinney will distribute to the Board members in mid-October and request feedback by the end of that month. Results will be provided to the Board.

VII. Other items were presented.

Dr. Smith suggested board members provide feedback to the NIH regarding cannabis-research barriers using the following link: <https://www.nccih.nih.gov/research/extramural/request-for-information-rfi-investigators-interests-in-and-barriers-to-research-studies-on-the-health-effects-of-cannabis-and-its-constituents>. It was considered that the ICR as a whole should submit input. Dr. Smith will draft and solicit bullet points and send to Board for review. Dr. Bidwell will contribute a "white paper" document used at CU as food for thought. Dr. Smith will identify deadline and distribute the materials.

Dr. Smith provided an update on ICR's collaboration with Vyripharm Enterprises Inc., noting that the ICR received the first payment and space was provided by the CSU-Pueblo Chemistry Dept. for their testing lab. This sets prominence and precedence so we can now enter into the arena of testing schedule 1 compounds. Dr. Sisley added; schedule 1 license for analytical testing is handled at the local level and is a familiar process that she would help the ICR navigate if desired. Dr. Bidwell and Dr. Sisley raised the value and independence of the ICR itself holding the Schedule 1 testing license. Dr. Bidwell would like to meet with Vyripharm during one of our GB meetings and requests that Dr. Smith work with her to set this up in the next few months.

VII. Public comment

Dr. Kinney attended and provided useful contributions to meeting.

VIII. The meeting was adjourned